Murine Glioblastoma Model
Murine Glioblastoma Model - Related Videos
02:29
Intravenous Administration of Therapeutic Nanoparticles in a Murine Glioblastoma Model
0 Views •
2025
Source: Kim, B. D., et al. Nanoparticle Delivery of an Oligonucleotide Payload in a Glioblastoma Multiforme Animal Model. J. Vis. Exp. (2024)This video demonstrates the intravenous injection of therapeutic nanoparticles in a glioblastoma-bearing mouse. The method enables targeted delivery across the blood-brain barrier and supports non-invasive imaging for evaluating nanoparticle biodistribution and therapeutic efficacy in brain tumors.
02:36
Generating a Glioblastoma Rat Model
0 Views •
2025
Source: Bolcaen, J., et. al., PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator. J. Vis. Exp. (2017)This video demonstrates the procedure for establishing a glioblastoma rat model by stereotactically injecting brain tumor-causing glioblastoma cells into the prefrontal cortex.
07:25
Two-Photon Intravital Microscopy of Glioblastoma in a Murine Model
0 Views •
Cited by 2 •
2024
We present a novel approach for two-photon microscopy of the tumor delivery of fluorescent-labeled iron oxide nanoparticles to glioblastoma in a mouse model.
09:17
Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma
0 Views •
Cited by 13 •
2016
GL261 glioma cells provide a useful immunocompetent animal model of glioblastoma. The goals of this protocol are to demonstrate proper techniques for monitoring intracranial tumor growth using in vivo bioluminescence imaging, and to verify the utility of luciferase-modified GL261 cells for studying tumor immunology and immunotherapeutic approaches for treating glioblastoma.
02:28
Bioluminescence Imaging of an Immunocompetent Mouse Model for Glioblastoma
0 Views •
2025
Source: Clark, A.J., et al. Bioluminescence Imaging of an Immunocompetent Animal Model for Glioblastoma. J. Vis. Exp. (2016)This video demonstrates bioluminescence imaging to track glioblastoma progression in an immunocompetent mouse model, using luciferase-expressing tumor cells and luciferin to quantify tumor growth non-invasively.
FAQs
The choice between syngeneic and xenograft systems determines which biological questions the experiment can address. Syngeneic models preserve immune compatibility, allowing tumor growth to be examined alongside an intact, relevant immune setting. Xenografts instead support investigation of human tumor biology. This distinction is especially important when interpreting immune suppression or treatment responses, because the model's immune relationship shapes the experimental context.
Within the brain, tumor cells do not act in isolation. Their growth is examined in relation to surrounding neural tissue, blood vessels, and immune cells, creating a tumor microenvironment that can influence progression and invasion. Studying these interactions helps investigators connect local tissue changes with glioblastoma behavior and identify how immune suppression contributes to the biology of the tumor.
By following how the tumor develops in brain tissue, investigators can study progression and invasive behavior rather than examining tumor cells only in isolation. The model also supports analysis of the brain tumor microenvironment, including interactions with neural tissue, vessels, and immune cells. These observations provide context for interpreting mechanisms relevant to neuro-oncology.
Immune compatibility determines whether the experimental system can meaningfully represent interactions between tumor cells and immune cells. Syngeneic models are therefore suited to examining immune suppression and testing immunotherapies in an immune-compatible setting. This makes them particularly relevant to Immunology and Infection, where the relationship between malignant cells and host immune responses is central.
The workflow begins by introducing glioblastoma cells into the mouse brain. Researchers then examine tumor growth within the brain, where the cells interact with neural tissue, blood vessels, and immune cells. The resulting system can be used to study progression, invasion, immune suppression, and responses to interventions, while keeping the biological setting controlled.
Selection should follow the biological question. A syngeneic system is appropriate when preserving immune compatibility is important, such as for studying immune suppression or immunotherapy. A xenograft is more useful when the focus is human tumor biology. Comparing these purposes prevents researchers from treating the two model types as interchangeable experimental systems.
The system supports investigation of immunotherapies, chemotherapies, and other treatment strategies in the context of a brain tumor. Researchers can assess these approaches alongside tumor progression, invasion, and the surrounding microenvironment. This contextual testing adds information beyond cellular studies and helps establish a bridge between controlled experiments and clinical research in neuro-oncology.
It places glioblastoma growth in contact with immune cells inside the brain, allowing investigators to examine immune suppression as part of tumor biology. At the same time, the model preserves the neuro-oncology context of neural tissue, vessels, and local tumor progression. This combined perspective supports research questions that extend beyond studies of tumor cells alone.